BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang XG, Jandl T, Dadachova E, Revskaya E. Effect of naive and radiolabeled rhTRAIL on the cervical cancer xenografts in mice. Ther Deliv 2014;5:139-47. [PMID: 24483193 DOI: 10.4155/tde.13.137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Ashique S, Upadhyay A, Kumar N, Chauhan S, Mishra N. Metabolic syndromes responsible for cervical cancer and advancement of nanocarriers for efficient targeted drug delivery- A review. Advances in Cancer Biology - Metastasis 2022;4:100041. [DOI: 10.1016/j.adcanc.2022.100041] [Reference Citation Analysis]
2 Rossignoli F, Spano C, Grisendi G, Foppiani EM, Golinelli G, Mastrolia I, Bestagno M, Candini O, Petrachi T, Recchia A, Miselli F, Rovesti G, Orsi G, Veronesi E, Medici G, Petocchi B, Pinelli M, Horwitz EM, Conte P, Dominici M. MSC-Delivered Soluble TRAIL and Paclitaxel as Novel Combinatory Treatment for Pancreatic Adenocarcinoma. Theranostics 2019;9:436-48. [PMID: 30809285 DOI: 10.7150/thno.27576] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 7.0] [Reference Citation Analysis]
3 Chen L, Luan S, Xia B, Liu Y, Gao Y, Yu H, Mu Q, Zhang P, Zhang W, Zhang S, Wei G, Yang M, Li K. Integrated analysis of HPV-mediated immune alterations in cervical cancer. Gynecol Oncol 2018;149:248-55. [PMID: 29572030 DOI: 10.1016/j.ygyno.2018.01.031] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
4 Gupta S, Gupta MK. Possible role of nanocarriers in drug delivery against cervical cancer. Nano Rev Exp 2017;8:1335567. [PMID: 30410707 DOI: 10.1080/20022727.2017.1335567] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 6.6] [Reference Citation Analysis]
5 Liu X, Li Y, He J, Zhao T, Chen C, Gu H, Wang X. Paclitaxel-loaded pluronic F127/P123 silica nanocapsules with surface conjugated rhTRAIL for targeted cancer therapy. RSC Adv 2017;7:30250-61. [DOI: 10.1039/c7ra04503d] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]